AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12699032 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment gain
Number of subjects: 87
Study 12699032 — intervention group
Group type: COMPARATOR
Intervention: Sudden within-treatment gain
Number of subjects: 87
Study 10960384 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine 0.2 mg (Group 1)
Number of subjects: 90
Study 10960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 0.2 mg (Group 2)
Number of subjects: 90
Study 10960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 0.8 mg (Group 3)
Number of subjects: 90
Study 10960384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 1.6 mg (Group 4)
Number of subjects: 90
Study 8800479 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h food deprivation
Number of subjects: 0
Study 8800479 — intervention group
Group type: COMPARATOR
Intervention: 1 h food deprivation
Number of subjects: 0
Study 8800479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall caloric intake during the entire laboratory day
Number of subjects: 0
Study 1629381 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 74
Study 1629381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6317737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg b.i.d.
Number of subjects: 382
Study 6317737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 29385952 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and Recovery Peer (HARP) program, a self‐management program for general medical conditions led by certified peer specialists; N=198
Number of subjects: 400
Study 29385952 — intervention group
Group type: COMPARATOR
Intervention: Usual care; N=202
Number of subjects: 400
Study 27026640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 6973
Study 27026640 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 6973
Study 24115083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical 100 U onabotulinumtoxinA injection
Number of subjects: 48
Study 24115083 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-diabetic patients)
Number of subjects: 48
Study 23911756 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 2248
Study 23911756 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐1 receptor blockers (ARB)
Number of subjects: 2248
Study 23911756 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors (ACE‐I)
Number of subjects: 2248
Study 23911756 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 2248
Study 23911756 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blockers (BB)
Number of subjects: 2248
Study 20100397 — intervention group
Group type: EXPERIMENTAL
Intervention: Social hand-shaking stimuli from a third-person perspective
Number of subjects: 0
Study 20100397 — intervention group
Group type: EXPERIMENTAL
Intervention: Inanimate effects (block arrow stimuli)
Number of subjects: 0
Study 20100397 — intervention group
Group type: EXPERIMENTAL
Intervention: Social action effects
Number of subjects: 0
Study 18228005 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.057 mg/kg)
Number of subjects: 28
Study 18228005 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta‐9‐THC (0.0286 mg/kg)
Number of subjects: 28
Study 18228005 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and Delta‐9‐THC
Number of subjects: 28
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 164
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery or curettage and cautery
Number of subjects: 164
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to specialist
Number of subjects: 164
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor visits
Number of subjects: 164
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 164
Study 16650155 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 164
Study 12091491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 1,000 mg/d
Number of subjects: 33
Study 12091491 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 33
Study 12091491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10995146 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy bupivacaine 0.5% (in dextrose 8%)
Number of subjects: 36
Study 10995146 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine 0.5% (dextrose-free)
Number of subjects: 36
Study 10995146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% in dextrose 4% (mixed)
Number of subjects: 36
Study 7480568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading (10 1-g tablets/day for 14 days)
Number of subjects: 36
Study 7480568 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (14 days)
Number of subjects: 36
Study 7480568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium loading
Number of subjects: 36
Study 7480568 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 36
Study 2403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant somatropin 0.1 mg/kg (0.27 IU/kg) three times weekly
Number of subjects: 121
Study 2403006 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 121
Study 2403006 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 pubertal children)
Number of subjects: 121
Study 2403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin 0.1 mg/kg (0.27 IU/kg) three times weekly (second year)
Number of subjects: 121
Study 2403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin 0.1 mg/kg (0.27 IU/kg) once-daily (second year)
Number of subjects: 121
Study 2403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Original treatment regimen (first year) continued (second year)
Number of subjects: 121
Study 2403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Changed to once-daily treatment at the same weekly dose (second year)
Number of subjects: 121
Study 6998598 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms
Number of subjects: 108
Study 6998598 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 micrograms
Number of subjects: 108
Study 6998598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 6998598 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (both dosages)
Number of subjects: 108
Study 6998598 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 108
Study 31097441 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 67
Study 31097441 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 67
Study 31848003 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundations for Safety Leadership (FSL) training program
Number of subjects: 20
Study 31848003 — intervention group
Group type: COMPARATOR
Intervention: Control group (lagged training)
Number of subjects: 20
Study 27465633 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance Training (VRT)
Number of subjects: 16
Study 27465633 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 16
Study 26178463 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Number of subjects: 15
Study 26178463 — intervention group
Group type: COMPARATOR
Intervention: NIV-PS
Number of subjects: 15
Study 24188065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 82
Study 24188065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 21070231 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 391
Study 21070231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 19438429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17394011 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised CO-rebreathing method (oCOR-method)
Number of subjects: 10
Study 17394011 — intervention group
Group type: COMPARATOR
Intervention: Former commonly used CO-rebreathing procedure
Number of subjects: 10
Study 12946941 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (1 kcal/min) with proximal (duodenal) distension (n = 8)
Number of subjects: 24
Study 12946941 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (1 kcal/min) with distal (rectal) distension (n = 8)
Number of subjects: 24
Study 12946941 — intervention group
Group type: COMPARATOR
Intervention: Sham distension (control group, n = 8)
Number of subjects: 24
Study 11705299 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 0
Study 11705299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 9531895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray applied to the cervix and cervical canal
Number of subjects: 300
Study 9531895 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 300
Study 8703650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 5
Study 8703650 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 5
Study 8703650 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 5
Study 8703650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 5
Study 8703650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 5 mg i.v.
Number of subjects: 50
Study 2084590 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study 732302 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position on bicycle ergometer
Number of subjects: 5
Study 732302 — intervention group
Group type: COMPARATOR
Intervention: Sitting position on bicycle ergometer
Number of subjects: 5
Study 30732732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery denervation (PADN)
Number of subjects: 98
Study 30732732 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil plus sham PADN
Number of subjects: 98
Study 28877232 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise (LRE) at 40% of one-repetition maximum
Number of subjects: 12
Study 28877232 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (HRE) at 80% of one-repetition maximum
Number of subjects: 12
Study 28877232 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - resting condition
Number of subjects: 12
Study 25774017 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Review with Follow-Up (MRF) service
Number of subjects: 1403
Study 25774017 — intervention group
Group type: COMPARATOR
Intervention: Normal medication dispensing (Control Group)
Number of subjects: 1403
Study 25774017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-Utility Analysis of MRF service
Number of subjects: 1403
Study 23883736 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 3 mm)
Number of subjects: 72
Study 23883736 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 9 mm)
Number of subjects: 72
Study 23883736 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 15 mm)
Number of subjects: 72
Study 23883736 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-P assessment based on OSASW at 9 mm and 15 mm
Number of subjects: 72
Study 21911633 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote physician-pharmacist team-based care
Number of subjects: 6963
Study 21911633 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6963
Study 19752505 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 142
Study 19752505 — intervention group
Group type: COMPARATOR
Intervention: Placebo QW
Number of subjects: 142
Study 19752505 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW (after 24 weeks)
Number of subjects: 142
Study 19752505 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo followed by Etanercept 50 mg QW
Number of subjects: 142
Study 16739839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electric stimulation using audio frequency pulse modulated wave
Number of subjects: 150
Study 16739839 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 150
Study 14507250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (HRT)
Number of subjects: 0
Study 14507250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (women not receiving HRT)
Number of subjects: 0
Study 10383519 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole b.d. (LAC15 group)
Number of subjects: 215
Study 10383519 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole b.d. (LAC30 group)
Number of subjects: 215
Study 8697755 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual stimulation
Number of subjects: 32
Study 8697755 — intervention group
Group type: COMPARATOR
Intervention: Unimanual stimulation
Number of subjects: 32
Study 1687852 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (625 mg orally) followed by adenosine infusion (40 micrograms kg‐1 min‐1 for 5 min, 60 micrograms kg‐1 min‐1 for 5 min, and 80 micrograms kg‐1 min‐1 for 30 min)
Number of subjects: 5
Study 1687852 — intervention group
Group type: COMPARATOR
Intervention: Placebo theophylline tablets followed by adenosine infusion
Number of subjects: 5
Study 1687852 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (625 mg orally)
Number of subjects: 5
Study 1687852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion only
Number of subjects: 5
Study 6366805 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg furosemide
Number of subjects: 36
Study 6366805 — intervention group
Group type: COMPARATOR
Intervention: 50 mg chlorthalidone
Number of subjects: 36
Study 6366805 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 36
Study 3554462 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened enzyme immunoassay (2 hours incubation)
Number of subjects: 4025
Study 3554462 — intervention group
Group type: COMPARATOR
Intervention: Normal enzyme immunoassay (3 hours 30 minutes incubation)
Number of subjects: 4025
Study 3554462 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened enzyme immunoassay
Number of subjects: 4025
Study 3554462 — intervention group
Group type: COMPARATOR
Intervention: Normal enzyme immunoassay
Number of subjects: 4025
Study 29745095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 53
Study 29745095 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin (PC)
Number of subjects: 53
Study 27619104 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (1 hour daily for 12 weeks)
Number of subjects: 40
Study 27619104 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine medical care only)
Number of subjects: 40
Study 23974633 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliotibial band autograft (ITB)
Number of subjects: 60
Study 23974633 — intervention group
Group type: COMPARATOR
Intervention: Bone-patella-tendon-bone autograft (BPTB)
Number of subjects: 60
Study 22499962 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin based on the weight-based dosing nomogram
Number of subjects: 25
Study 22499962 — intervention group
Group type: COMPARATOR
Intervention: Control group (not following the standard nomogram)
Number of subjects: 25
Study 20565212 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation of several different distractor items with increased distractor interval
Number of subjects: 0
Study 20565212 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated articulations of the same word between list items
Number of subjects: 0
Study 20565212 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of distractors
Number of subjects: 0
Study 20565212 — intervention group
Group type: EXPERIMENTAL
Intervention: Total duration of distractors
Number of subjects: 0
Study 18294739 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals
Number of subjects: 46
Study 18294739 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 15792395 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg via Diskus, twice daily
Number of subjects: 14
Study 15792395 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg via Diskus, single dose
Number of subjects: 14
Study 12527527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 ml)
Number of subjects: 65
Study 12527527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 ml)
Number of subjects: 65
Study 10389800 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA) with Boyle Davis (B-D) gag
Number of subjects: 20
Study 10389800 — intervention group
Group type: COMPARATOR
Intervention: Flexible laryngeal mask airway (FLMA) without Boyle Davis (B-D) gag
Number of subjects: 20
Study 10389800 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway (FLMA)
Number of subjects: 20
Study 8542688 — intervention group
Group type: EXPERIMENTAL
Intervention: External spinal skeletal fixation
Number of subjects: 0
Study 8542688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 1871399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy survey by midwives at home for the prevention of prematurity
Number of subjects: 0
Study 1871399 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of prevention of ill-treatment of very young children
Number of subjects: 0
Study 1871399 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of prevention of sexually transmitted diseases and their complications on sterility
Number of subjects: 0
Study 1871399 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign to support women deciding to breast-feed
Number of subjects: 0
Study 6875167 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating gratings treatment (n = 20)
Number of subjects: 38
Study 6875167 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18) - viewed a blank rotating disc for 15 minutes once a week for ten weeks
Number of subjects: 38
Study 30639752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 face‐to‐face visits with a psychologist and exercise specialist over 3 months
Number of subjects: 0
Study 30639752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 face‐to‐face visits with a psychologist and exercise specialist over 3 months plus technology‐based behavior change support package for an additional 6 months
Number of subjects: 0
Study 30639752 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 29795283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-water bathing
Number of subjects: 75
Study 29795283 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 27763623 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ) in 2005
Number of subjects: 970
Study 27763623 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical COPD Questionnaire (CCQ) in 2012
Number of subjects: 970
Study 27763623 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis including baseline CCQ, sex, age, educational level, BMI, smoking status, heart disease, diabetes, depression, number of exacerbations, dyspnoea (mMRC)
Number of subjects: 970
Study 25241544 — intervention group
Group type: EXPERIMENTAL
Intervention: OUYA FIBER posts
Number of subjects: 120
Study 25241544 — intervention group
Group type: COMPARATOR
Intervention: Tenax Fiber White posts
Number of subjects: 120
Study 22176795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) delivered via contraceptive vaginal ring, 600-800 mcg
Number of subjects: 39
Study 20307949 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLC/MS/MS method for simultaneous determination of furosemide, spironolactone, and canrenone
Number of subjects: 0
Study 18039282 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods including Oldham's method and multilevel modelling
Number of subjects: 0
Study 18039282 — intervention group
Group type: COMPARATOR
Intervention: ANCOVA
Number of subjects: 0
Study 16330998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trident insert encased in a titanium sleeve
Number of subjects: 316
Study 16330998 — intervention group
Group type: COMPARATOR
Intervention: Alumina bearing couple
Number of subjects: 316
Study 12025827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681
Study 12025827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681
Study 12025827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Nefazodone + CBASP)
Number of subjects: 681
Study 12025827 — intervention group
Group type: COMPARATOR
Intervention: CBASP
Number of subjects: 681
Study 10584048 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnivorous diet (mixed-diet group)
Number of subjects: 19
Study 10584048 — intervention group
Group type: COMPARATOR
Intervention: Lactoovovegetarian diet (LOV-diet group)
Number of subjects: 19
Study 10584048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19